GlassScriptPhysician profile
Emily B Harris
NPI 1821638842
$4,895.00
in general payments reported to CMS, 2019-2025
28 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $287 · 2023: $753 · 2024: $1,454 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,190 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,189.78 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $983.28 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $640.18 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $434.55 | 2023-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.50 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $263.96 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $260.62 | 2024-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $213.60 | 2023-2025 | Glassia |
| Verona Pharma, INC. | $189.20 | 2025 | Ohtuvayre |
| Genzyme Corporation | $157.05 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $148.84 | 2025 | Winrevair |
| Inspire Medical Systems, INC. | $141.46 | 2023-2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $140.46 | 2023-2025 | Nuzyra |
| Ani Pharmaceuticals, INC. | $135.14 | 2023-2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $133.74 | 2023-2024 | Yupelri |
| Electromed, INC. | $107.26 | 2023-2025 | Smartvest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $99.85 | 2022-2025 | Hillrom - Volara System, Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $98.16 | 2024-2025 | Arikayce, Brinsupri |
| Bayer Healthcare Pharmaceuticals INC. | $78.23 | 2023 | |
| Amgen INC. | $66.36 | 2021-2025 | Tezspire |
| Advanced Respiratory, INC | $58.82 | 2021 | |
| Harmony Biosciences LLC | $45.95 | 2024 | |
| Viatris Specialty LLC | $44.83 | 2025 | Yupelri |
| Philips North America LLC | $40.84 | 2023-2025 | Vest Therapy Und |
| Abbvie INC. | $40.18 | 2021 | |
| Vifor Pharma, INC. | $28.54 | 2025 | Zemaira |
| Genentech USA, INC. | $19.73 | 2025 | Xolair |
| Grifols USA, LLC | $17.60 | 2024 | Prolastin-C Liquid |
| Pulmonx Corporation | $17.07 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.